Decongestion Strategies for Ambulatory Outpatients: The Proof Is in the Urine.

Competing Interests: Funding Support and Author Disclosures Dr Felker has received research grants from NHLBI, Amgen, Bayer, BMS, Novartis, Daxor, Merck, Cytokinetics, and CSL-Behring; has received consulting fees from Novartis, Amgen, BMS, Cytokinetics, Innolife, Medtronic, Cardionomic, Boehringer-Ingelheim, Astra-Zeneca, Regeneron, Reprieve, Myovant, Sequana, Windtree Therapeutics, Rocket Pharma, and Whiteswell; and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, and LivaNova. Dr Rambarat has reported that she has no relationships relevant to the contents of this paper to disclose.